{"id":"https://openalex.org/W7225778489","doi":"https://doi.org/10.5281/zenodo.24128015","title":"IN-SILICO DESIGN, SYNTHESIS AND EVALUATION OF NOVEL PYRAZINE-COUMARIN HYBRID DERIVATIVE AS EGFR INHIBITORS FOR GLIOBLASTOMA THERAPY","display_name":"IN-SILICO DESIGN, SYNTHESIS AND EVALUATION OF NOVEL PYRAZINE-COUMARIN HYBRID DERIVATIVE AS EGFR INHIBITORS FOR GLIOBLASTOMA THERAPY","publication_year":2026,"publication_date":"2026-11-11","ids":{"openalex":"https://openalex.org/W7225778489","doi":"https://doi.org/10.5281/zenodo.24128015"},"language":"en","primary_location":{"id":"doi:10.5281/zenodo.24128015","doi":"https://doi.org/10.5281/zenodo.24128015","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.24128015","pdf_url":null,"source":{"id":"https://openalex.org/S76264521","display_name":"Degr\u00e9s","issn_l":"0376-8163","issn":["0376-8163"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","jufo-1","poland-20","russia-white-list-4"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.5281/zenodo.24128015","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5161425939","display_name":"Seba M C, Ardra krishnan R, Athulya S Rajan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Seba M C, Ardra krishnan R, Athulya S Rajan","raw_affiliation_strings":["The Dale View College of Pharmacy and Research centre, (Autonomous), Punalal P O, Thiruvananthapuram"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Dale View College of Pharmacy and Research centre, (Autonomous), Punalal P O, Thiruvananthapuram","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5161425939"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.8676999807357788,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.8676999807357788,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.10649999976158142,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14099","display_name":"Synthesis and Characterization of Heterocyclic Compounds","score":0.020800000056624413,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.8434000015258789},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.7835999727249146},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.7055000066757202},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5307000279426575},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5180000066757202},{"id":"https://openalex.org/C41685203","wikidata":"https://www.wikidata.org/wiki/Q1974042","display_name":"Docking (animal)","level":2,"score":0.4772999882698059},{"id":"https://openalex.org/C2776194525","wikidata":"https://www.wikidata.org/wiki/Q282142","display_name":"Glioblastoma","level":2,"score":0.4758000075817108},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.43950000405311584},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4226999878883362},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.3682999908924103},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.3617999851703644},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.34790000319480896},{"id":"https://openalex.org/C3018146709","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Anticancer drug","level":3,"score":0.34689998626708984},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.34360000491142273},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.3312999904155731},{"id":"https://openalex.org/C116073593","wikidata":"https://www.wikidata.org/wiki/Q864491","display_name":"Biological activity","level":3,"score":0.3253999948501587},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.30790001153945923},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.3075999915599823},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3005000054836273},{"id":"https://openalex.org/C26375932","wikidata":"https://www.wikidata.org/wiki/Q118226","display_name":"Growth factor receptor","level":3,"score":0.2678000032901764},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.26330000162124634},{"id":"https://openalex.org/C176944494","wikidata":"https://www.wikidata.org/wiki/Q1415380","display_name":"Point mutation","level":4,"score":0.2624000012874603},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2612000107765198},{"id":"https://openalex.org/C2989108626","wikidata":"https://www.wikidata.org/wiki/Q904407","display_name":"Drug target","level":2,"score":0.257099986076355},{"id":"https://openalex.org/C111771559","wikidata":"https://www.wikidata.org/wiki/Q66295","display_name":"Derivative (finance)","level":2,"score":0.25270000100135803}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.5281/zenodo.24128015","doi":"https://doi.org/10.5281/zenodo.24128015","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.24128015","pdf_url":null,"source":{"id":"https://openalex.org/S76264521","display_name":"Degr\u00e9s","issn_l":"0376-8163","issn":["0376-8163"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","jufo-1","poland-20","russia-white-list-4"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"},{"id":"doi:10.5281/zenodo.24128016","doi":"https://doi.org/10.5281/zenodo.24128016","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.24128016","pdf_url":null,"source":{"id":"https://openalex.org/S76264521","display_name":"Degr\u00e9s","issn_l":"0376-8163","issn":["0376-8163"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","jufo-1","poland-20","russia-white-list-4"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"doi:10.5281/zenodo.24128015","doi":"https://doi.org/10.5281/zenodo.24128015","is_oa":true,"landing_page_url":"https://doi.org/10.5281/zenodo.24128015","pdf_url":null,"source":{"id":"https://openalex.org/S76264521","display_name":"Degr\u00e9s","issn_l":"0376-8163","issn":["0376-8163"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","jufo-1","poland-20","russia-white-list-4"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"ABSTRACTGlioblastoma":[0],"(GBM)":[1],"is":[2],"an":[3],"aggressive":[4],"primary":[5],"brain":[6],"tumour":[7],"associated":[8],"with":[9,95],"tumourheterogeneity,":[10],"resistance":[11],"to":[12,27,42,51],"therapy":[13],"and":[14,30,56,58,69,107,113,127,138],"limited":[15],"drug":[16,37],"deliveryacross":[17],"the":[18,90,99],"blood\u2013brain":[19],"barrier.Epidermal":[20],"growth":[21,29],"factor":[22],"receptor":[23],"(EGFR)":[24],"alterations":[25],"contribute":[26],"GBM":[28],"survival,making":[31],"EGFR":[32,52,84,144],"animportant":[33],"target":[34],"for":[35,133],"anticancer":[36],"discovery.":[38],"This":[39],"study":[40],"aimed":[41],"designpyrazine\u2013coumarin":[43],"hybrid":[44],"derivatives,":[45],"assess":[46],"their":[47,49],"drug-likeness,evaluate":[48],"predictedbinding":[50],"by":[53,109],"molecular":[54],"docking,":[55],"synthesize":[57],"preliminarily":[59],"characterize":[60],"aselected":[61],"compound.":[62],"Ten":[63],"analogues(PC1\u2013PC10)":[64],"were":[65],"drawn":[66],"using":[67],"ChemSketch":[68],"assessedusing":[70],"SwissADME.":[71],"All":[72],"ten":[73],"compounds":[74],"showed":[75],"zero":[76],"violations":[77],"of":[78,81],"Lipinski\u2019s":[79],"Rule":[80],"Five.Docking":[82],"against":[83],"(PDB":[85],"ID:":[86],"8SC7)":[87],"gave":[88],"PC1":[89],"most":[91],"favourable":[92],"score":[93],"(-8.1),compared":[94],"erlotinib":[96],"(-6.7)":[97],"in":[98],"reported":[100],"docking":[101],"results.A":[102],"selected":[103],"pyrazine\u2013coumarinester":[104],"was":[105,118],"synthesized":[106],"examined":[108],"thin-layer":[110],"chromatography":[111],"(TLC)":[112],"melting-pointdetermination;":[114],"itsreported":[115],"melting":[116],"point":[117],"150\u00b0C,":[119],"while":[120],"7-hydroxy-4-methylcoumarinmelted":[121],"at":[122],"115\u00b0C.":[123],"These":[124],"preliminary":[125],"computational":[126],"physicochemicalfindings":[128],"identify":[129],"PC1as":[130],"a":[131],"candidate":[132],"further":[134,150],"investigation.":[135],"Docking":[136],"scores":[137],"basic":[139],"characterization":[140],"alone":[141],"donot":[142],"establish":[143],"inhibition":[145],"oranti-glioblastoma":[146],"efficacy;":[147],"these":[148],"require":[149],"analyticaland":[151],"biological":[152],"validation.":[153]},"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-11-12T00:00:00"}